japanese encephalitis virus vaccine + dengue vaccine

This combination refers to the co-administration or combined clinical evaluation of two live-attenuated chimeric vaccines developed by Sanofi Pasteur using the **ChimeriVax** technology platform. The Japanese Encephalitis (JE) component, known as **IMOJEV** (CYD-JEV), and the tetravalent dengue component, known as **Dengvaxia** (CYD-TDV or CYD-1,2,3,4), both utilize the Yellow Fever 17D virus vaccine strain as a genetic backbone. In these constructs, the pre-membrane (prM) and envelope (E) genes of the Yellow Fever virus are replaced with those of the target flaviviruses (JE virus or the four dengue serotypes DENV-1, 2, 3, and 4). This approach induces a robust immune response, including neutralizing antibodies and cellular immunity, while maintaining the safety profile of the attenuated Yellow Fever backbone. Clinical studies have specifically evaluated the safety and immunogenicity of co-administering these vaccines to simplify immunization schedules in regions where both diseases are endemic.

Brand names

IMOJEVDengvaxia

Other names

japanese encephalitis virus vaccine + CYD-1,2,3,4 dengue vaccinetetravalent dengue vaccinelive-attenuated chimeric Japanese encephalitis vaccineCYD tetravalent dengue vaccine